Т.В. Статкевич, Н.П. Митьковская
УО «Белорусский государственный медицинский университет», Республиканский научно-практический центр «Кардиология», Минск, Республика Беларусь
Хроническая сердечная недостаточность (ХСН) представляет собой важную не только медицинскую, но и социально-экономическую проблему для государства. Наличие синдрома ХСН не только значительно повышает риски неблагоприятного течения заболеваний, лежащих в его этиологической основе, но и само по себе через развитие декомпенсаций обуславливает высокую частоту смертельных исходов. Несмотря на все успехи фармакотерапии, прогноз у пациентов с сердечной недостаточностью остается неблагоприятным. Более 40% пациентов умирают в течение 4 лет после постановки диагноза сердечной недостаточности, а однолетняя смертность пациентов с тяжелой ХСН (класс IV по NYHA) превышает 50%. Вышеизложенное обуславливает необходимость и важность использования всех возможных медикаментозных и немедикаментозных технологий терапии, направленных на снижение смертности, увеличение продолжительности и качества жизни пациентов с ХСН, а также снижающих количество и вероятность декомпенсаций и связанных с ними госпитализаций, и делает это направление одним из самых приоритетных в медицине. В статье изложены современные подходы к лечению пациентов с синдромом ХСН с позиции доказательной медицины и с учетом рекомендаций ведущих международных организаций по лечению и профилактике сердечно-сосудистых заболеваний. Используемые лекарственные препараты проанализированы с позиции влияния на клиническую симптоматику, качество жизни пациентов, риск госпитализации в связи с декомпенсацией ХСН, а также показатели смертности. Сделан акцент на возможностях, механизме действия и дальнейших перспективах применения нового класса лекарственных препаратов в терапии ХСН, действующего на уровне ренин-ангиотензин-альдостероновой системы и системы нейтральных эндопептидаз – ингибитора рецепторов ангиотензина-неприлизина.
ключевые слова: хроническая сердечная недостаточность, медикаментозная терапия, ингибиторы рецепторов ангиотензина-неприлизина

для цитирования: Т.В. Статкевич, Н.П. Митьковская. Современные аспекты медикаментозной терапии синдрома хронической сердечной недостаточности. Неотложная кардиология и кардиооваскулярные риски, 2020, Т. 4, № 2, С. 1085–1096

Current aspects of drug therapy of chronic heart failure syndrome
T.V. Statkevich, N.P. Mitkovskaya
Chronic heart failure (CHF) is an important problem for the country, which has both medical and socio-economic aspects. The presence of the syndrome not only significantly increases the risks of an unfavorable course of diseases underlying its etiological basis, but in itself, through the development of decompensation, causes a high frequency of deaths. Despite all the advances in pharmacotherapy, the prognosis of heart failure remains poor. More than 40% of patients die within 4 years after the diagnosis of heart failure, and the one-year mortality rate for patients with severe CHF (NYHA class IV) exceeds 50%. The foregoing determines the need and importance of using all possible drug and non-drug therapy technologies aimed at reducing mortality, increasing the duration and quality of life of patients with CHF, as well as reducing the number and likelihood of decompensation and related hospitalizations, and makes this direction one of the priorities in medicine. The article describes current approaches to the treatment of patients with CHF syndrome from the perspective of evidence-based medicine and taking into account the recommendations of leading international organizations for the treatment and prevention of cardiovascular diseases. The drugs used were analyzed in terms of their influence on clinical symptoms, quality of life of patients, the risk of hospitalization due to decompensation of CHF, and mortality rates. The emphasis is made on the possibilities, mechanism of action and further prospects for the use of a new class of drugs in the treatment of CHF, acting at the level of the renin-angiotensin-aldosterone system and the system of neutral endopeptidases – inhibitors of angiotensin-neprilisin receptors.
keywords: chronic heart failure, drug therapy, angiotensin-neprilisin receptor inhibitors

for references: T.V. Statkevich, N.P. Mitkovskaya. Current aspects of drug therapy of chronic heart failure syndrome. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2020, vol. 4, no. 2, pp. 1085–1096

1. Adams K.F., Ghali J.K., Patterson J.H., Stough W.J., Butler J., Bauman J.L., Ventura Y., Sabbah H., Mackowiak J.I., Veldhuisen D.J. A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur J Heart Fail, 2014, vol. 16, no. 5, pp. 483-493. doi: 10.1002/ejhf.64.
2. Ambrosy A.P., Braunwald E., Morrow D.A., DeVore A.D. McCague K., Meng X., Duffy C.I., Rocha R., Velazquez E.J. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol, 2020, vol. 76, no. 9, pp.1034-1048. doi: 10.1016/j.jacc.2020.06.073.
3. Ambrosy A.P., DeVore A.D., Velazquez E.J. In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail, 2019, vol. 21, no. 8, pp.1008-1011. doi: 10.1002/ejhf.1540.
4. Bavishi C., KhanA.R., Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol, 2015, vol. 188, pp. 99-101. doi: 10.1016/j.ijcard.2015.04.031.
5. Böhm M., Borer J., Ford I., Gonzalez-Juanatey J.R., Komajda M., Lopez-Sendon J, Reil J-C, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol, 2013, vol. 102, no. 1, pp. 11-22. doi: 10.1007/s00392-012-0467-8.
6. Burnett H., Earley A., Voors A., Senni M., McMurray J.J.V., Deschaseaux C., Cope S. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail, 2017, vol. 10, no. 1, pp. e003529. doi: 10.1161/CIRCHEARTFAILURE.116.003529.
7. Chatterjee S., Biondi-Zoccai G., Abbate A., D'Ascenzo F., Castagno D., Van Tassell B., Mukherjee D., Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ, 2013, vol. 16, no. 346, pp. f55. doi: 10.1136/bmj.f55.
8. Cunningham J.W., Claggett B.L., O'Meara E., Prescott M.F., Pfeffer M.A., Shah S.J., Redfield M.M., Zannad F., Chiang L.M., Rizkala A.R., Victor C Shi V.C., Lefkowitz M.P., Rouleau J., McMurray J., Solomon S.D., Zile M.R. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol, 2020, vol. 76, no. 5, pp.503-514. doi: 10.1016/j.jacc.2020.05.072.
9. Cunningham J.W., Vaduganathan M., Claggett B.L., Zile M.R., Anand I.S., Packer M., Zannad F., Lam C., Janssens S., Jhund P.S., Kober L., Rouleau J., Shah S.J., Chopra V.K., Shi V.C., Lefkowitz M.P., Prescott M.F., Pfeffer M.A., McMurray J., Solomon S.D. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail, 2020, vol. 8, no. 5, pp. 372-381. doi: 10.1016/j.jchf.2020.03.002.
10. Desai A.S., Solomon S.D., Shah A.M., Claggett B.L., Fang J.C., Izzo J., McCague K., Abbas C.A., Rocha R., Mitchell G.F. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 2019, vol. 322, no. 11, pp. 1-10. doi: 10.1001/jama.2019.12843.
11. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997, vol. 336, no. 8, pp. 525-533. doi: 10.1056/NEJM199702203360801.
12. Drazner M.H. Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. JAMA, 2019, vol. 322, no. 11, pp. 1051-1053. doi: 10.1001/jama.2019.12662.
13. Dunlay S.M., Roger V.L. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep, 2014, vol. 11, no. 4, pp. 404-415. doi: 10.1007/s11897-014-0220-x.
14. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol, 2002, vol. 82, no. 2, pp. 149-158. doi: 10.1016/s0167-5273(01)00600-3.
15. Faris R., Flather M., Purcell H., Poole-Wilson P., Coats A. Diuretics for heart failure. Cochrane Database Syst Rev, 2012, vol. 15, no. 2, pp. CD003838. doi: 10.1002/14651858.CD003838.pub3.
16. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA, 1995, vol. 273, pp. 1450-456.
17. Gaziano T.A., Fonarow G.C., Velazquez E.J., Morrow D.A., Braunwald E., Solomon S.D. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, 2020. doi: 10.1001/jamacardio.2020.2822. Online ahead of print.
18. Gheorghiade M., Shah A.N., Vaduganathan M., Butler J., Bonow R.O., Rosano G.M.C., Taylor S., Kupfer S., Misselwitz F., Sharma A., Fonarow G.C. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Fail Clin, 2013, vol. 9, no. 3, pp.285-290. doi: 10.1016/j.hfc.2013.05.002.
19. Gori M., Volterrani M., Piepoli M., Senni M. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. Int J Cardiol, 2017, vol. 226, pp. 136-140. doi: 10.1016/j.ijcard.2016.06.083.
20. Januzzi Jr J.L., Prescott M.F., Butler J., Felker G.M., Maisel A.S., McCague K., Camacho A., Piña I.L., Rocha R.A., Shah A.M., Williamson K.M., Solomon S.D. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA, 2019, vol. 322, no. 11, pp. 1-11. doi: 10.1001/jama.2019.12821.
21. Kazuomi K. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Curr Cardiol Rep, 2018, vol. 20, no. 5. doi: 10.1007/s11886-018-0944-4.
22. Maggioni A.P., Anker S.D., Dahlstrom U., Filippatos G., Ponikowski P., Zannad F., Amir O., Chioncel O., Leiro M.C., Drozdz J., Erglis A., Fazlibegovic E., Fonseca C., Fruhwald F., Gatzov P., Goncalvesova E., Hassanein M., Hradec J., Kavoliuniene A., Lainscak M., Logeart D., Merkely B., Metra M., Persson H., Seferovic P., Temizhan A., Tousoulis D., Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail, 2013, vol. 15, no. 10, pp. 1173-1184. doi: 10.1093/eurjhf/hft134.
23. Maisel A., Mueller C., Adams K., Anker S.D., Aspromonte N., Cleland J.G.F., Cohen-Solal A., Dahlstrom U., DeMaria A., DiSomma S., Filippatos G.S., Fonarow G.C., Jourdain P., Komajda M., Liu P.P., McDonagh T., McDonald K., Mebazaa A., Nieminen M.S., Peacock W.F., Tubaro M., Valle R., Vanderhyden M., Yancy C.W., Zannad F.,Braunwald E. State of the ar t: using natriuretic peptide levels in clinical prac tice. Eur J Heart Fail, 2008, vol. 10, no. 9, pp. 824-839. doi: 10.1016/j.ejheart.2008.07.014.
24. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. Angiotensin-neprilysin inhibition versus enalapril in hear t failure. N Engl J Med, 2014, vol. 371, no. 11, pp. 993-1004.
25. Miles J.A., Hanumanthu B.K., Patel K., Chen M., Siegel R.M., Kokkinidis D.J. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med, 2019, vol. 20, no. 6, pp. 379-388. doi: 10.2459/JCM.0000000000000794.
26. Miller L.V., Missov E.D. Epidemiology of heart failure. Cardiol Clin, 2001, vol. 19, no. 4, pp. 547-555. doi: 10.1016/s0733-8651(05)70242-3.
27. Morrow D.A., Velazquez E.J., DeVore A.D., Desai A.S., Duffy C.I., Ambrosy A.P., Gurmu Y., McCague K., Rocha R., Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation, 2019, vol. 139, no. 19, pp. 2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.
28. Nochioka K., Sakata Y., Shimokawa H. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure. Adv Exp Med Biol, 2018, vol. 1067, pp. 17-30. doi: 10.1007/5584_2018_179.
29. Orso F., Fabbri G., Maggioni A. Epidemiology of Heart Failure. Handb Exp Pharmacol, 2017, vol. 243, pp. 15-33. doi: 10.1007/164_2016_74.
30. Papademetriou V., Toumpourleka M., Imprialos K.P., Alataki S., Manafis A., Stavropoulos K. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Curr Pharm Des, 2018, vol. 24, no. 46, pp. 5517-5524. doi: 10.2174/1381612825666190219141326.
31. Pascual-Figal D., Wachter R., Senni M., Bao W., Noè A., Schwende H., Butylin D., Prescott M.F. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart Fail, 2020, vol. 8, no. 10, pp. 822-833. doi: 10.1016/j.jchf.2020.05.012.
32. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J., Coats A., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G., Ruilope L.M., Ruschitzka F., Rutten F.H., Van Der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail, 2016, vol. 18, no. 8, pp. 891-975. doi: 10.1002/ejhf.592.
Формат файла: pdf (446.78 Кб)